The action of CDKi in compensating the defects of the cell cycle regulatory mechanism and restraining cell division has provided a strong rationale to evaluate the therapeutic benefits of CDKi in the context of HER2+ BC too. The gene discussed is ERBB2; the disease is breast cancer.